Investee Companies

Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

Acorn Partners Limited

Product:
Life Sciences
Status:
Open
Sector:
Medical technologies
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

Deepbridge Capital LLP has seeded Acorn Partners Ltd, an efficient new way of originating, developing and delivering innovation within the broader healthcare space. In collaboration with our execution partners at WeAreNova and Europe’s largest children’s hospital Alder Hey, we redefine the... Read more

Aurio Limited

Product:
Life Sciences
Status:
Closed
Sector:
Tinnitus Technology
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

Aurio Limited has developed a patentable core technology that potentially eases the debilitating effects of tinnitus. 

Tinnitus is a perception of sound in the absence of an external source. Although it is often referred to as ‘ringing in the ears’, tinnitus can also be perceived as... Read more

Beamline Diagnostics Limited

Product:
Life Sciences
Status:
Open
Sector:
Cancer Diagnosis
Aim of funding:
Growth
HMRC Advance Assurance received:
Yes

BeamLine Diagnostics was set up to commercialise research in to the application of infrared spectroscopy to the diagnosis of cancer. Cancer is a worldwide problem with over 14 million new diagnoses and 8 million deaths recorded in 2012 alone (according to Cancer Research UK statistics, May 2015... Read more

CareCube Solutions

Product:
Life Sciences
Status:
Closed
Sector:
Digital workflow
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

Care Cube Solutions Ltd (‘CCSL’) is a networked digital workflow system designed by cardiologists for users to simplify and centralise the complex tracking of patient flow in cardiology departments. In doing so, the technology seeks to safeguard patients from human error, and also assists... Read more

Elasmogen

Product:
Life Sciences
Status:
Open
Sector:
Drug discovery
Aim of funding:
Growth
HMRC Advance Assurance received:
Yes

Elasmogen Ltd is a biologics company spun out of the University of Aberdeen in Feb 2016 and has developed a validated and IP-protected ‘soloMER’ platform. ‘soloMer’ refers to employ of small proteins as a site-specific drug delivery mechanism for ophthalmology and solid tumour cancers.

... Read more

EligoChem Limited

Product:
Life Sciences
Status:
Open
Sector:
Drug design
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

EligoChem has developed a proprietary and patentable technology that facilitates the design of highly water-soluble drugs that are absorbed well by the human body.  One in fifteen known drug compounds have this combination of properties, but they are present in only one in ten thousand... Read more

eLucid mHealth Limited

Product:
Life Sciences
Status:
Open
Sector:
Medical Technology
Aim of funding:
Growth
HMRC Advance Assurance received:
Yes

eLucid mHealth is a medication technology company creating proprietary, patented automatic adherence/compliance monitoring tools as part of an integrated healthcare system.

eLucid mHealth’s solutions and devices have been specifically designed with patient feedback; they are non-invasive... Read more

Fen EP

Product:
Life Sciences
Status:
Closed
Sector:
Sudden Cardiac Death prevention
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

PEFA (‘paced electrogram fractionation analysis’) is a unique procedure and was invented by cardiologist Dr Richard Saumarez , initially when based at St Georges Hospital, London, and subsequently developed and tested at the University of Cambridge and Papworth Hospital.

The procedure... Read more

Filisia Interfaces Limited

Product:
Life Sciences
Status:
Closed
Sector:
Training Technology
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

Filisia addresses the training, rehabilitation and access requirements of people with special education and rehabilitation needs through creative and connected technology.       

Filisia estimates that there are over 150 million people globally with... Read more

Ibis Vision Limited

Product:
Life Sciences
Status:
Open
Sector:
Glaucoma Detection
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve... Read more

New Path Molecular Research

Product:
Life Sciences
Status:
Closed
Sector:
Molecule research
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

The Company was established in January 2015 by Professor Steven Ley at the University of Cambridge, following his observation that, due to industry developments such as the reduction in internal R&D spending and out-sourcing to low cost economies, access to the most creative and innovative... Read more

Parkure Limited

Product:
Life Sciences
Status:
Closed
Sector:
Parkinsons Research
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

The Company’s primary intention is the discovery of drugs that can prevent or inhibit the progression of Parkinson’s disease (‘PD’), for which there is currently no cure. Parkure’s primary goal is to discover and co-develop drugs that stop the disease progression; the Company will also exploit... Read more

PeptigelDesign Limited

Product:
Life Sciences
Status:
Closed
Sector:
Hydrogel Production
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

PeptiGelDesign Limited provides formulated ready-to-use and easy-to-handle hydrogels for culture dishes, multi-well plates, or cell culture inserts, used in research laboratories. PeptigelDesign believe the research services market is large and growing, estimating it to be worth c.$20bn on a... Read more

Purius

Product:
Life Sciences
Status:
Closed
Sector:
Pharmaceuticals
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

The Company was established in 2016 to exploit opportunities within the pharmaceutical sector, specifically delivering a solution to reduce manufacturing costs and increase output. To do so, the Company has established a novel technological process called ‘zero step purification’. The... Read more

Renephra Limited

Product:
Life Sciences
Status:
Open
Sector:
Medical Technology
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

Renephra Ltd is a UK based medical device development company that has developed and patented a disruptive technology that addresses the significant ongoing medical problems associated with treatment resistance of fluid overload within the body. Health issues often associated with fluid... Read more

Stent Tek Limited

Product:
Life Sciences
Status:
Closed
Sector:
Catheter Technology
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

The Company is developing a novel catheter system that enables patients to receive haemodialysis (‘HD’) in an improved manner. Currently, patients receiving HD must undergo a surgical procedure to create a surgical connection between an artery and a vein, the vein then acts as a ‘vascular... Read more

Transcriptogen Limited

Product:
Life Sciences
Status:
Closed
Sector:
Cancer Treatment
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

Transcriptogen Ltd has developed a new approach to the treatment of cancer.  The Company has developed a lead molecule, TSG1301, which has been shown to be highly effective at treating Breast and Pancreatic Cancer in human tumours that have been grafted onto mice. In addition, it appears... Read more

Viscgo

Product:
Life Sciences
Status:
Closed
Sector:
Medical measurement
Aim of funding:
Seed
HMRC Advance Assurance received:
Yes

Viscgo was founded in August 2015 by Dr Elizabeth Boaden and Mr Steven Bookbinder to solve the medical need for consistently and accurately measuring the viscosity of differing drinks and textured modified foods for those people being treated with differing levels of dysphagia (i.e. swallowing... Read more